Paroxetine in panic disorder: clinical management and long-term follow-up

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Dismrlers. Fourth Edition. American Psychiatric Association Inc., Washington DC, USA (1994).
   Google Scholar
• Dyckman JM, Rosenbaum RL, Hartmeyer RJ, Walter U. Effects of psychological intervention on panic attack patients in the emergency department. Bychosomatics 40, 22–427 (1999).
   Web of Science ®Google Scholar
• Leon AC, Potera L, Weissman MM. The social costs of anxiety disorders. BE J:P9rhiatry166 (Suppl.), 19–22 (1995).
   Google Scholar
• Hofmann S, Barlow DH. The costs of anxiety disorders. In: Cost Effectiveness of P9rhotherapy: Guide for Practitioners, Researchers and Policymakers. Miller NE, Magruder KM (Eds). Oxford University Press Inc., NY, USA, 224–243 (1999).
   Google Scholar
• Salvador-Carulla L, Segui J, Fernandez- Cano P, Canet J. Costs and offset effects in panic disorders. BE J: Psychiatry 166(Suppl.), 23–28 (1995).
   Google Scholar
• Kessler RC, McGonagle IKA, Zhao S et al Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Adh. Gen. Psychiatry 51, 8–19 (1994).
   Google Scholar
• Pollack, MET, Smoller JVV The longitudinal course and outcome of panic disorder. P9rhiatr Clin. North Am. 18(4), 785–801 (1995).
   Google Scholar
• Weissman MM, Bland RC, Canino GJ et al The cross-national epidemiology of panic disorder. Arch. Gen. Psychiatry 54, 305–309 (1997).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guidelines for the treatment of patients with panic disorder. Am. J: Psychiatry 155 (Suppl.), 1–34 (1998).
   Google Scholar
• ••The American Psychatric Association (APA)mcomrnends that, selective serotonin reuptake inhibitors should be considered as first-line agents in the treatment of panic disoider since, while they have equal efficacy to the older agents, they are better tolerated with a more favorable side effect profile. The APA also recommends that phamlacotherapy for panic disorder (PD) should be continued for at least 1 year.
   Google Scholar
• Barlow DH, Gorman JM, Shear MK, Woods SW Cognitive—behavioral therapy, imipramine or their combination for panic disorder, a randomized controlled trial. JA M4 283,2529–2536 (2000).
   Google Scholar
• •Randomized controlled trial (n = 312) which demonstrates that combined pharrnacotherapy and cognitive behavioral therapy (CBT) for PD is better than either therapy alone in the maintenance phase.
   Google Scholar
• Mavissakalian MR, Perel JM. Imipramine treatment of panic disorder with agoraphobia. Am. J: P9rhiatry152, 673–682 (1995).
   Google Scholar
• Sheehan DV. The treatment of panic and phobic disorders. In: Clinical Bychopharmacology Second Edition. Bernstein JC (Ed.). John Wright-PSG, MA, USA (1984).
   Google Scholar
• Ballenger JC, Burrows G, DuPont R et al Alprazolam in panic disorder and agoraphobia: results from a multicenter trial: efficacy in short-term treatment. Arch. Gen. Psychiatry 45, 10–16 (1988).
   Web of Science ®Google Scholar
• Fyer, AJ, Leibowitz MR, Gorman JM et al Discontinuation of alprazolam treatment in panic patients. Am. J. PTchiatry144, 303–308 (1987).
   PubMed Web of Science ®Google Scholar
• Otto MW Tuby KS, Gould RA, Mclean RY, Pollack MET. An effect—size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am j Bychiatry158(12), 1989–1992 (2001).
   PubMed Web of Science ®Google Scholar
• Bakker A, van Balkom AJ, Spinhoven SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta PTchiatr. Scand. 106(3), 163–167 (2002).
   Google Scholar
• Keltner NL, Folks DG. PTchotropic Drug. Second Edition. Mosby-Year Book Inc., PA, USA (1997).
   Google Scholar
• Lydiard RB, Steiner M, Burnham D et al Efficacy studies of paroxetine in panic disorder. PTchophatmacol Bull. 34(2), 175–182 (1998).
   Google Scholar
• Pollack MET, Doyle AC. Treatment of panic disorder: focus on paroxetine. Psychopharmacol Bull 37(1), 53–63 (2003).
   PubMedGoogle Scholar
• ••Discusses a series of randomized, double-blind, placebo-controlled studies which have demonstrated the safety and efficacy of paroxetine in the treatment of PD. These studies show that most patients achieve a panic-free status during 12-week studies. Maintenance paroxetine treatment was shown to result in sustained rates of remission compared with placebo.
   Google Scholar
• Oehrberg S, Christiansen PE, Behnke K et al Paroxetine in the treatment of panic disorder a randomised, double-blind, placebo-controlled study. BE J. Psychiatry 167,374–379 (1995).
   PubMed Web of Science ®Google Scholar
• •Multicenter randomized, controlled trial (n = 120) compares the efficacy and tolerability of paroxetine with placebo in the short-term treatment of PD. All study patients received CBT. The results showed that combination paroxetine and CBT was more effective than CBT plus placebo in reducing the number of panic attacks.
   Google Scholar
• Ballenger GC, Wheadon DE, Steiner M et al Double-blind, fixed-dose placebo-controlled study of paroxetine in the treatment of panic disorder. Am. J. fiychiatry155(1), 36–42 (1998).
   Google Scholar
• Bakkar A, Van-Dyck R Spinhoven P et al Paroxetine, clomopramine and cognitive therapy in the treatment of panic disorder. Clin. PTchiatry60(12), 831–838 (1999).
   PubMed Web of Science ®Google Scholar
• Lecrubier Y, Bakker A, Dunber G et al A comparison of paroxetine, clompiramine and placebo in the treatment of panic disorder. Acta Psych. Scand 95,145–152 (1997).
   PubMed Web of Science ®Google Scholar
• Judge R, Burnham D, Steiner M et al Paroxetine long-term safety and efficacy in panic disorder and prevention of relapse: a double-blind study. Eur. Neuropsychopharmacol 6\(Suppl. 1), 26–28 (1996).
   Google Scholar
• •Randomized placebo-controlled trial examines the efficacy of paroxetine versus placebo in the maintenance phase. Patients who received paroxetine had a significantly lower relapse rate than the patients who received placebo.
   Google Scholar
• Lecrubier Y, Judge R. Collaborative paroxetine panic study investigators. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Bychiatr. Scand 95,153–160 (1997).
   Google Scholar
• Simon NM, Safren SA, Otto MW et al Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder. J. Affect. Dis. 69,201–208 (2002).
   PubMed Web of Science ®Google Scholar
• •• Randomized, double-blind, three-arm study in patients with PD (n = 60), which found that combined treatment with paroxetine and clonezeparn resulted in a more rapid response than with paroxetine alone but the differential benefits of combination therapy were apparent in the initial few weeks of therapy only and were not sustained in the maintenance phase.
   Google Scholar
• Toni C, Perugi G, Frare F et al A prospective naturalistic study of 326 panic—agoraphobic patients treated with antidepressants. Pharmacopsychiatry 33 (4) 121–131 (2000).
   Google Scholar
• O'Rourke D, Fahy TJ, Brophy J et al The Galway study of panic disorder III: outcome at 5–6 years. Br. Psych. 168, 462–469 (1996).
   Google Scholar
• Dannon PN Iancu I, Grunhaus U. Short- term potentiation of paroxetine with clonezepam in the treatment of patients with panic disorder. APA Annual Meeting, Washington DC, May 15–29,1999. American Psychiatric Association Press, Washinton DC, USA, 153 (1999).
   Google Scholar
• Mavissakalian MR, Perel JM. Second year maintenance and discontinuation of imipramine in PD and agoraphobia. Ann. Clin. Psych. 13,63–67 (2001).
   PubMedGoogle Scholar
• Physicians Desk Reference. 56th Edition. Medical Economics Co., NJ, USA (2002).
   Google Scholar
• Kuhn NA, Pastuszak A, Sage SR et al Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JA/V/4 279,609–610 (1998).
   Google Scholar
• Nordeng H, Lindemann R, Prminov KV et al Neonatal withdrawl syndrome after inutero exposure to selective serotonin reuptake inhibitors. Acta Paediatrica 90, 288–291 (2001) .
   PubMed Web of Science ®Google Scholar
• Misri S, Kim J, Riggs KW Kostaras X. Paroxetine levels in postpartum depressed women, breast milk and infant serum. J. Clin. Psych. 61,828–832 (2000).
   Google Scholar
• Stowe ZN, Cohen LS, Hostetter A et al Paroxetine in human breast milk and nursing infants. Am. J. PTchiatry257, 185–189 (2000).
   Web of Science ®Google Scholar
• Davidson JR. The long-term treatment of panic disorder. J. Clin. Psych. 59 (Suppl. 8), 17–21 (1998).
   Google Scholar
• Clayton AH, Pradko JF, Croft HA et al Prevalence of sexual dysfunction among newer antidepressants. J. Clin. Psych. 63, 357–366 (2002).
   Web of Science ®Google Scholar
• Zajecka J, Mitchell S, Fawcett J. Treatment- emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharmacol Buff. 33(4), 755–760 (1997).
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Eisfeld BS, Dickens SE et al Antidepressant induced sexual dysfunction during treatment with moclebemide, paroxetine, sertraline and venlafaxine. Clin. Psych. 61(4), 276–281(2000).
   Web of Science ®Google Scholar
• Wittchen HU, Whao S, Kessler RC et al DSM III-R generalized anxiety disorder in the National Comorbidity Survey. Arch. Gen. fiychiatry51,355–364 (1994).
   PubMed Web of Science ®Google Scholar
• Rickets K, Zaninelli, R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J. Psychiatry160(4), 749–756 (2003).
   Google Scholar
• Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissmann MM. Social Phobia: comorbidity and morbidity in an epidemiological sample. Arch. Gen. PTchiatry 49, 282–288 (1992).
   Google Scholar
• Stein MB, Leibowitz MR, Lydiard B et al Paroxetine treatment of generalized social phobia (social anxiety disorder), a randomized controlled trial. JA/V/A 280 (8), 708–813 (1998).
   Google Scholar
• Dannon P. Comorbid cannabis use and panic disorder: short-term and long-term follow-up study. Human fiychopharm. Clin. Experimental (2004) (In Press).
   Google Scholar
• Goddard AW, Brouette T, Almai A. Early coadministration of clonezepam with sertraline for panic disorder. Arch. Gen. Psych. 58,681–686 (2001).
   PubMed Web of Science ®Google Scholar
• Pollack MET, Simon NM, Worthington JJ et al . Combined paroxetine and clonezepam treatment strategies compared to paroxetine monotherapy for panic disorder. J. Psychopharmacology17(3), 276–282 (2003).
   PubMed Web of Science ®Google Scholar
• Salzman C. Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse. I Psych. Research 27,97–100 (1993).
   PubMed Web of Science ®Google Scholar
• Clark DM, Salkovskis PM, Hackmann A, Wells A, Ludgate J, Gelder M. Brief cognitive therapy for panic disorder: a randomized controlled trial. j Consult. Clin. PTchol. 4,583–589 (1999).
   Web of Science ®Google Scholar
• Schmidt NB, Wollaway-Bickel K, Trakowski JH, Santiago HT, Vasey M. Antidepressant discontinuation in the context of cognitive—behavioral treatment for panic disorder. Behav. Res. Ther. 40(1), 67–73 (2002).
   Google Scholar
• Otto MW, Pollack MET, Penava SJ, Zucker BG. Group cognitive—behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: a clinical case series. Behav. Res. Ther. 37(8), 763–770 (1999).
   Google Scholar
• Telch, MJ Lucas JA, Schmidt NB et al Group cognitive—behavioral treatment of panic disorder. Behav Res. Ther. 31, 279–287 (1993).
   PubMed Web of Science ®Google Scholar
• Bruce SE, Vasile RG, Goisman RM, Salzman C. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am j Bychiatry 160 (8), 1432–1438 (2003).
   Google Scholar
• Benjamin J, Ben-Zion IZ, Karbofsky E, Dannon P Double-blind placebo-controlled pilot study of paroxetine for specific phobia. PTchopharmacology (Berl) 149(2), 194–196 (2000).
   PubMed Web of Science ®Google Scholar